Your browser doesn't support javascript.
loading
The pathogenesis of Parkinson's disease.
Morris, Huw R; Spillantini, Maria Grazia; Sue, Carolyn M; Williams-Gray, Caroline H.
Affiliation
  • Morris HR; Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK; University College London Movement Disorders Centre, University College London, London, UK; Aligning Science Across Parkinson's Collaborative Research Network, Chevy Chase,
  • Spillantini MG; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK; Aligning Science Across Parkinson's Collaborative Research Network, Chevy Chase, MD, USA.
  • Sue CM; Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; Department of Neurology, South Eastern Sydney Local Health District, Sydney, NSW, Australia; Aligning Science Across Parkinson's Collaborative Research Network, Chevy Chase, MD, USA; Neuroscience Research Australia, Randwick
  • Williams-Gray CH; John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Lancet ; 403(10423): 293-304, 2024 Jan 20.
Article in En | MEDLINE | ID: mdl-38245249
ABSTRACT
Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease have been derived from genetics and molecular pathology. Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease. At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches. Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease. Although there are currently no disease-modifying treatments for Parkinson's disease, we now have a solid basis for the development of rational neuroprotective therapies that we hope will halt the progression of this disabling neurological condition.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease Type of study: Etiology_studies Limits: Animals / Humans Language: En Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Parkinson Disease Type of study: Etiology_studies Limits: Animals / Humans Language: En Year: 2024 Type: Article